

NATURAL ALTERNATIVES INTERNATIONAL INC
Form 10-Q
February 17, 2009
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
QUARTERLY REPORT
pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2008

000-15701

(Commission file number)

NATURAL ALTERNATIVES INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State of incorporation)

84-1007839
(IRS Employer Identification No.)

1185 Linda Vista Drive

San Marcos, California 92078
(Address of principal executive offices)

(760) 744-7340
(Registrant's telephone number)

Indicate by check mark whether Natural Alternatives International, Inc. (NAI) (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that NAI was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x Yes No

Edgar Filing: NATURAL ALTERNATIVES INTERNATIONAL INC - Form 10-Q

Indicate by check mark whether NAI is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether NAI is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of February 17, 2009, 7,066,526 shares of NAI's common stock were outstanding, net of 180,941 treasury shares.

Table of Contents

TABLE OF CONTENTS

	Page
<u>SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS</u>	1
PART I <u>FINANCIAL INFORMATION</u>	2
Item 1. <u>Financial Statements</u>	2
<u>Condensed Consolidated Balance Sheets</u>	2
<u>Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income</u>	3
<u>Condensed Consolidated Statements of Cash Flows</u>	4
<u>Notes to Condensed Consolidated Financial Statements</u>	5
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	13
Item 4. <u>Controls and Procedures</u>	18
PART II <u>OTHER INFORMATION</u>	19
Item 1. <u>Legal Proceedings</u>	19
Item 1A. <u>Risk Factors</u>	19
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	19
Item 3. <u>Defaults Upon Senior Securities</u>	19
Item 4. <u>Submission of Matters to a Vote of Security Holders</u>	19
Item 5. <u>Other Information</u>	19
Item 6. <u>Exhibits</u>	19
<u>SIGNATURES</u>	24

Table of Contents

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

Certain statements in this report, including information incorporated by reference, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect current views about future events and financial performance based on certain assumptions. They include opinions, forecasts, intentions, plans, goals, projections, guidance, expectations, beliefs or other statements that are not statements of historical fact. Words such as may, will, should, could, would, expects, plans, believes, anticipates, intends, estimates, ap projects, or the negative or other variation of such words, and similar expressions may identify a statement as a forward-looking statement. Any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, are forward-looking statements. Forward-looking statements in this report may include statements about:

future financial and operating results, including projections of net sales, revenue, income or loss, net income or loss per share, profit margins, expenditures, liquidity, goodwill valuation and other financial items;

our ability to develop relationships with new customers and maintain or improve existing customer relationships;

development of new products, brands and marketing strategies;

the effect of the discontinuance of Dr. Cherry's television program and our ability to develop a new marketing plan for, and to sustain, our Pathway to Healing® product line;

distribution channels, product sales and performance, and timing of product shipments;

inventories and the adequacy and intended use of our facilities;

current or future customer orders;

the impact on our business and results of operations and variations in quarterly net sales from seasonal and other factors;

management's goals and plans for future operations;

our ability to improve operational efficiencies, manage costs and business risks and improve or maintain profitability;

growth, expansion, diversification, acquisition, divestment and consolidation strategies, the success of such strategies, and the benefits we believe can be derived from such strategies;

personnel;

Edgar Filing: NATURAL ALTERNATIVES INTERNATIONAL INC - Form 10-Q

the outcome of regulatory, tax and litigation matters;

sources and availability of raw materials;

operations outside the United States;

the adequacy of reserves and allowances;

overall industry and market performance;

competition;

current and future economic and political conditions;

the impact of accounting pronouncements; and

other assumptions described in this report underlying or relating to any forward-looking statements.

The forward-looking statements in this report speak only as of the date of this report and caution should be taken not to place undue reliance on any such forward-looking statements. Forward-looking statements are subject to certain events, risks, and uncertainties that may be outside of our control. When considering forward-looking statements, you should carefully review the risks, uncertainties and other cautionary statements in this report as they identify certain important factors that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These factors include, among others, the risks described under Item 1A of Part II and elsewhere in this report, as well as in other reports and documents we file with the United States Securities and Exchange Commission (SEC).

Unless the context requires otherwise, all references in this report to the Company, NAI, we, our, and us refer to Natural Alternatives International, Inc. and, as applicable, Natural Alternatives International Europe S.A. (NAIE), Real Health Laboratories, Inc. (RHL) and our other wholly owned subsidiaries.

Table of Contents**PART I FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****NATURAL ALTERNATIVES INTERNATIONAL, INC.****Condensed Consolidated Balance Sheets****(In thousands, except share and per share data)**

	December 31, 2008 (Unaudited)	June 30, 2008
Assets		
Current assets:		
Cash and cash equivalents	\$ 3,337	\$ 3,518
Certificate of deposit	699	
Accounts receivable - less allowance for doubtful accounts of \$8 at December 31, 2008 and \$17 at June 30, 2008	4,638	6,401
Inventories, net	13,613	14,135
Income tax receivable	1,270	1,354
Prepays and other current assets	974	1,223
Current assets of discontinued operations	3,316	6,299
Total current assets	27,847	32,930
Property and equipment, net	14,039	12,823
Other noncurrent assets, net	159	160
Total assets	\$ 42,045	\$ 45,913
Liabilities and Stockholders Equity		
Current liabilities:		
Accounts payable	\$ 5,935	\$ 7,245
Accrued liabilities	1,173	1,048
Accrued compensation and employee benefits	1,274	1,332
Income taxes payable	405	409
Line of credit	3,538	
Current portion of long-term debt	1,994	2,730
Current liabilities of discontinued operations	833	1,724
Total current liabilities	15,152	14,488
Deferred income taxes		61
Deferred rent	1,114	1,164
Long-term pension liability	223	198
Total liabilities	16,489	15,911
Commitments and contingencies		
Stockholders equity:		
Preferred stock; \$0.01 par value; 500,000 shares authorized; none issued or outstanding	71	71

Edgar Filing: NATURAL ALTERNATIVES INTERNATIONAL INC - Form 10-Q

Common stock; \$0.01 par value; 20,000,000 shares authorized; issued and outstanding 7,247,467 at December 31, 2008 and 7,210,937 at June 30, 2008		
Additional paid-in capital	18,741	18,485
Accumulated other comprehensive loss	(261)	(261)
Retained earnings	8,104	12,806
Treasury stock, at cost, 180,941 shares at December 31, 2008 and June 30, 2008	(1,099)	(1,099)
Total stockholders' equity	25,556	30,002
Total liabilities and stockholders' equity	\$ 42,045	\$ 45,913

See accompanying notes to condensed consolidated financial statements.

Table of Contents**NATURAL ALTERNATIVES INTERNATIONAL, INC.****Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income****(In thousands, except share and per share data)****(Unaudited)**

	Three Months Ended December 31,		Six Months Ended December 31,	
	2008	2007	2008	2007
Net sales	\$ 17,616	\$ 18,402	\$ 37,142	\$ 41,287
Cost of goods sold	16,844	15,226	33,970	34,171
Gross profit	772	3,176	3,172	7,116
Selling, general & administrative expenses	2,838	3,075	5,456	5,967
Operating (loss) income from continuing operations	(2,066)	101	(2,284)	1,149
Other income (expense):				
Interest income		11	5	13
Interest expense	(79)	(39)	(122)	(182)
Foreign exchange (loss) gain	(45)	48	(344)	150
Other, net	4	(28)	28	
	(120)	(8)	(433)	(19)
(Loss) income from continuing operations before income taxes	(2,186)	93	(2,717)	1,130
Provision (benefit) for income taxes	362	(49)	180	237
(Loss) income from continuing operations	(2,548)	142	(2,897)	893
Loss from discontinued operations, net of tax	(756)	(322)	(1,804)	(650)
Net (loss) income	\$ (3,304)	\$ (180)	\$ (4,701)	\$ 243
Unrealized gain resulting from change in fair value of derivative instruments, net of tax		14		22
Comprehensive (loss) income	\$ (3,304)	\$ (166)	\$ (4,701)	\$ 265
Net (loss) income per common share:				
Basic:				
Continuing operations	\$ (0.36)	\$ 0.02	\$ (0.41)	\$ 0.13
Discontinued operations	(0.11)	(0.05)	(0.26)	(0.09)
Net (loss) income	\$ (0.47)	\$ (0.03)	\$ (0.67)	\$ 0.03
Diluted:				
Continuing operations	\$ (0.36)	\$ 0.02	\$ (0.41)	\$ 0.12
Discontinued operations	(0.11)	(0.05)	(0.26)	(0.09)
Net (loss) income	\$ (0.47)	\$ (0.03)	\$ (0.67)	\$ 0.03

Edgar Filing: NATURAL ALTERNATIVES INTERNATIONAL INC - Form 10-Q

Weighted average common shares outstanding:

Basic	7,057,614	6,980,195	7,045,413	6,947,155
Diluted	7,057,614	7,067,113	7,045,413	7,044,402

See accompanying notes to condensed consolidated financial statements.

Table of Contents**NATURAL ALTERNATIVES INTERNATIONAL, INC.****Condensed Consolidated Statements of Cash Flows****(In thousands)****(Unaudited)**

	Six Months Ended December 31,	
	2008	2007
Cash flows from operating activities		
(Loss) income before discontinued operations	\$ (2,897)	\$ 893
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:		
Change in allowance for uncollectible accounts receivable	(9)	1
Depreciation and amortization	1,547	1,497
Non-cash compensation	181	195
Tax benefit from exercise of stock options	(88)	(64)
Deferred income taxes	(61)	
Pension expense, net of contributions	25	25
Loss on disposal of assets	8	69
Changes in operating assets and liabilities:		
Accounts receivable	1,772	(544)
Inventories, net	522	1,093
Other assets	250	37
Accounts payable and accrued liabilities	(1,237)	(612)
Income taxes payable	168	62
Accrued compensation and employee benefits	(58)	64
Net cash provided by operating activities from continuing operations	123	2,716
Net cash (used in) operating activities from discontinued operations	(1,866)	(358)
Net cash (used in) provided by operating activities	(1,743)	2,358
Cash flows from investing activities		
Capital expenditures	(2,771)	(705)
Purchase of certificate of deposit	(699)	
Net cash used by investing activities from continuing operations	(3,470)	(705)
Net cash provided by (used in) investing activities from discontinued operations, including proceeds from the sale of As We Change	2,155	(18)
Net cash used by investing activities	(1,315)	(723)
Cash flows from financing activities		
Net borrowings on line of credit	3,538	
Payments on long-term debt	(736)	(892)
Tax benefit from exercise of stock options	88	64
Repurchase of common stock		(724)
Net activity from issuance of common stock	(13)	432
Net cash provided by (used in) financing activities	2,877	(1,120)

Edgar Filing: NATURAL ALTERNATIVES INTERNATIONAL INC - Form 10-Q

Net (decrease) increase in cash and cash equivalents	(181)	515
Cash and cash equivalents at beginning of period	3,518	4,095
Cash and cash equivalents at end of period	\$ 3,337	\$ 4,610
Supplemental disclosures of cash flow information		
Cash paid during the period for:		
Interest	\$ 140	\$ 211
Taxes	\$ 60	\$ 419

See accompanying notes to condensed consolidated financial statements.

Table of Contents**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****(UNAUDITED)****A. Basis of Presentation and Summary of Significant Accounting Policies****Basis of Presentation**

The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and applicable rules and regulations. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In management's opinion, all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows have been included and are of a normal, recurring nature. The results of operations for the three and six months ended December 31, 2008 are not necessarily indicative of the operating results for the full fiscal year or any future periods.

You should read the financial statements and these notes, which are an integral part of the financial statements, together with our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2008 (2008 Annual Report). The accounting policies used to prepare the financial statements included in this report are the same as those described in the notes to the consolidated financial statements in our 2008 Annual Report unless otherwise noted below.

Reclassification

Certain prior year amounts have been reclassified to conform with the current year's presentation. Such reclassifications had no effect on net (loss) income.

Net (Loss) Income per Common Share

We compute net income per common share in accordance with Statement of Financial Accounting Standards (SFAS) No. 128, *Earnings Per Share*. This statement requires the presentation of basic income per common share, using the weighted average number of common shares outstanding during the period, and diluted net income per common share, using the additional dilutive effect of all dilutive securities. The dilutive impact of stock options account for the additional weighted average shares of common stock outstanding for our diluted net income per common share computation. We calculated basic and diluted net income per common share as follows (in thousands, except per share data):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2008	2007	2008	2007
Numerator				
Net (loss) income	\$ (3,304)	\$ (180)	\$ (4,701)	\$ 243
Denominator				
Basic weighted average common shares outstanding	7,058	6,980	7,045	6,947
Dilutive effect of stock options		87		97
Diluted weighted average common shares outstanding	7,058	7,067	7,045	7,044
Basic net (loss) income per common share	\$ (0.47)	\$ (0.03)	\$ (0.67)	\$ 0.03
Diluted net (loss) income per common share	\$ (0.47)	\$ (0.03)	\$ (0.67)	\$ 0.03

Shares related to stock options of 879,492 for the three months ended December 31, 2008, and 973,096 for the six months ended December 31, 2008, were excluded from the calculation of diluted net (loss) income per common share, as the effect of their inclusion would have been anti-dilutive.

Edgar Filing: NATURAL ALTERNATIVES INTERNATIONAL INC - Form 10-Q

Shares related to stock options of 577,000 for the three months ended December 31, 2007, and 552,000 for the six months ended December 31, 2007, were excluded from the calculation of diluted net (loss) income per common share, as the effect of their inclusion would have been anti-dilutive.

Stock-Based Compensation

We have an equity incentive plan under which we have granted nonqualified and incentive stock options to employees, non-employee directors and consultants. We also have an employee stock purchase plan. Effective July 1, 2005, we adopted the fair value recognition provisions of SFAS No. 123R, *Share Based Payment* (SFAS 123R), using the modified-prospective-transition method. Under that transition method, compensation cost is recognized (a) for all stock-based awards granted before, but not yet vested as of, July 1, 2005, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123, *Accounting*

Table of Contents

for *Stock Based Compensation*, and (b) for all stock-based awards granted after July 1, 2005, based on the grant date fair value estimated in accordance with the provisions of SFAS 123R. Results for periods before implementation of SFAS 123R have not been restated.

We estimated the fair value of the stock option awards at the date of grant and employee stock purchase plan shares at the beginning of the offering period using the Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Option valuation models require the input of highly subjective assumptions. Black-Scholes uses assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities used in the model are based mainly on the historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect in the period of grant. The expected life of stock option grants is derived from historical experience.

Our net loss for the three months ended December 31, 2008 included stock based compensation expense of approximately \$112,000. Our net loss for the three months ended December 31, 2007 included stock based compensation expense of approximately \$100,000. Our net loss included stock-based compensation expense of approximately \$181,000 for the six months ended December 31, 2008. Our net income was reduced by stock-based compensation expense of approximately \$195,000 for the six months ended December 31, 2007.

Adoption of New Accounting Standards

Effective July 1, 2008, the Company adopted SFAS No. 157, *Fair Value Measurements* (SFAS 157) for its financial assets and liabilities. In February 2008, the Financial Accounting Standards Board (FASB) issued FASB Staff Position (FSP) No. FAS 157-2, *Effective Date of FASB Statement No. 157*, which delayed the effective date of SFAS 157 for nonfinancial assets and liabilities, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually), to fiscal years beginning after November 15, 2008 and interim periods within those fiscal years. SFAS 157 establishes a framework for measuring fair value under generally accepted accounting principles and expands disclosures about fair value measurement. The adoption of SFAS 157 on July 1, 2008 did not have any effect on the Company's consolidated financial statements.

In February 2007, the FASB issued SFAS No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities – Including an amendment of FASB Statement No. 115* (SFAS 159), effective as of the beginning of the first fiscal year that begins after November 15, 2007. SFAS 159 permits entities to choose to measure many financial instruments and certain other items at fair value with changes in fair value recognized in earnings for each reporting period. The adoption of SFAS 159 on July 1, 2008 did not have any effect on the Company's consolidated financial statements as the Company did not elect any eligible items for fair value measurement.

B. Discontinued Operations

On August 4, 2008, RHL sold certain assets related to its catalog and internet business conducted under the name *As We Change*® to Miles Kimball Company for a cash purchase price of \$2,000,000. The purchase price was subject to certain post-closing adjustments based on a final accounting of the value of the assets sold to and the liabilities assumed by the buyer at the closing. As a result of the post-closing review, the purchase price was increased by \$299,000, resulting in an aggregate purchase price of \$2,299,000. We recorded a loss, net of tax, of \$148,000 as a result of this sale and we recognized \$221,000 in severance and related payroll costs during the six months ended December 31, 2008.

We intend to market for sale legacy RHL's remaining business operations during fiscal 2009, with the exception of our *Pathway to Healing*® product line. As the plan to dispose of the legacy RHL business met the criteria of SFAS No. 144, *Accounting for the Disposal of Long-lived Assets* (SFAS 144), the current and prior periods presented in this report have been reclassified to reflect the legacy RHL business as discontinued operations.

As a result of our decision to sell the legacy RHL business, we also initiated an operational consolidation program during the first quarter of fiscal 2009 that transitioned the remaining branded products business operations to our corporate offices. This operational consolidation program was substantially complete as of September 30, 2008 and resulted in a charge to discontinued operations of \$829,000 in severance and other business related exit costs during the six months ended December 31, 2008.

Table of Contents

The following table presents the activity and the reserve balances related to these restructuring programs for the six months ended December 31, 2008 (in thousands):

	Balance at June 30, 2008	Charges to Expense	Cash Payments	Balance at December 31, 2008
Employee termination costs	\$	\$ 919	\$ (673)	\$ 246
Lease liabilities and related facility closure costs		131	(36)	95
Total	\$	\$ 1,050	\$ (709)	\$ 341

Accrued restructuring charges:

Current portion continuing operations	\$	12
Discontinued operations		329
Total	\$	341

The following table summarizes the results of the legacy RHL business, classified as discontinued operations, for the periods ended December 31 (in thousands):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2008	2007	2008	2007
Net sales	\$ 800	\$ 2,009	\$ 2,174	\$ 4,645
Cost of goods sold and operating expense	724	2,382	2,691	5,396
Restructuring expenses	199		1,050	
Loss on the sale of As We Change®			226	
Other expense	12	19	11	37
Loss before income taxes	(135)	(392)	(1,804)	(788)
Income tax provision (benefit)	621	(70)		(138)
Loss from discontinued operations	\$ (756)	\$ (322)	\$ (1,804)	\$ (650)

Assets and liabilities of the legacy RHL business included in the Condensed Consolidated Balance Sheets are summarized as follows (in thousands):

	December 31, 2008	June 30, 2008
Assets		
Cash	\$ 357	\$ 575
Accounts receivable, net	551	349
Inventory, net	324	805
Other current assets	38	204
Plant and equipment, net		351
Goodwill and intangible assets	2,046	4,015
Total assets	\$ 3,316	\$ 6,299
Liabilities		

Edgar Filing: NATURAL ALTERNATIVES INTERNATIONAL INC - Form 10-Q

Accounts payable	\$	\$ 678
Accrued liabilities	833	1,046
Total liabilities	833	1,724
Net assets of discontinued operations	\$ 2,483	\$ 4,575

C. Inventories

Inventories, net consisted of the following (in thousands):

	December 31, 2008	June 30, 2008
Raw materials	\$ 10,072	\$ 10,428
Work in progress	2,410	2,517
Finished goods	2,213	1,997
Reserves	(1,082)	(807)
	\$ 13,613	\$ 14,135

Table of Contents**D. Property and Equipment**

Property and equipment consisted of the following (dollars in thousands):

	Depreciable Life In Years	December 31, 2008	June 30, 2008
Land	N/A	\$ 393	\$ 393
Building and building improvements	7 39	2,727	2,723
Machinery and equipment	3 12	22,483	19,963
Office equipment and furniture	3 5	3,825	3,774
Vehicles	3	204	204
Leasehold improvements	1 15	10,382	10,283
Total property and equipment		40,014	37,340
Less: accumulated depreciation and amortization		(25,975)	(24,517)
Property and equipment, net		\$ 14,039	\$ 12,823

E. Debt

We have a bank credit facility of \$9.5 million, comprised of a \$7.5 million working capital line of credit and \$2.0 million in outstanding term loans. The working capital line of credit is secured by our accounts receivable and other rights to payment, general intangibles, inventory and equipment, has a fluctuating or fixed interest rate as elected by NAI from time to time and described in more detail below, and borrowings are subject to eligibility requirements for current accounts receivable and inventory balances. The working capital line of credit has no pre-determined minimum monthly payments and matures on November 1, 2010. As of December 31, 2008 the outstanding balances on the term loans consisted of a \$280,000, 15 year term loan due June 2011, secured by our San Marcos building, at an interest rate of 8.25%; a \$540,000, 10 year term loan due May 2014 with a twenty year amortization, secured by our San Marcos building, at an interest rate of LIBOR plus 2.25%; a \$140,000, five year term loan due May 2009, secured by equipment, at an interest rate of LIBOR plus 2.10%; and a \$1.0 million, four year term loan due December 2009, secured by equipment, at an interest rate of LIBOR plus 2.10%. Monthly payments on the term loans are approximately \$124,000 plus interest. As of December 31, 2008, we had \$3.5 million outstanding on the working capital line of credit.

On January 24, 2007, we amended our credit facility to extend the maturity date for the working capital line of credit from November 1, 2007 to November 1, 2008, and maintain the ratio of total liabilities/tangible net worth covenant at 1.25/1.0 for the remainder of the term of the credit facility.

On December 18, 2007, we further amended our credit facility to (i) extend the maturity date for the working capital line of credit from November 1, 2008 to November 1, 2009; (ii) reduce the maximum principal amount available under the working capital line of credit from \$12.0 million to \$7.5 million; (iii) reduce the maximum borrowings against inventory from \$6.0 million to \$3.75 million, provided any such borrowings do not at any time exceed eligible accounts receivable; and (iv) extend the availability of the Foreign Exchange Facility from November 1, 2007 to November 1, 2008 and the allowable contract term thereunder from November 1, 2008 to November 1, 2009. Our lender agreed to extend the availability of the Foreign Exchange Facility from November 1, 2008 to November 1, 2010 effective as of November 1, 2008.

On December 29, 2008, we again amended our credit facility to (i) extend the maturity date for the working capital line of credit from November 1, 2009 to November 1, 2010; (ii) modify the interest rate payable on the line of credit from a rate equal to the Prime Rate or LIBOR plus 1.75%, as elected by NAI from time to time, to a rate equal to either a fluctuating rate per annum equal to 2.75% to 3.75% above the Daily One Month LIBOR Rate in effect from time to time or a fixed rate per annum equal to 2.50% to 3.50% above LIBOR, as elected by NAI from time to time, in each case with the percentage above the applicable LIBOR determined based on NAI's fixed charge coverage ratio; (iii) modify the fiscal year end net income requirement for fiscal 2009 from net income after taxes of not less than \$750,000 to a net loss not to exceed \$2,500,000; (iv) modify the fixed charge coverage ratio for the quarter ending March 31, 2009 from not less than 1.25 to 1.0 to not less than 0.50 to 1.0; and (v) eliminate the fixed charge coverage ratio and net income requirements that would have applied to the second quarter of fiscal 2009. In consideration of such amendments, NAI paid a \$25,000 amendment fee to the lender.

Edgar Filing: NATURAL ALTERNATIVES INTERNATIONAL INC - Form 10-Q

Based on the impact of our deferred tax asset valuation (as described under Note J below) and our cumulative losses from operations over the previous four fiscal quarters, we do not expect to meet our fixed charge coverage ratio covenant as of March 31, 2009. If we fail to meet this covenant, we intend to request a waiver from our lender but there is no assurance when or if or on what terms a waiver will be provided. Therefore, in accordance with SFAS No. 78, *Classification of Obligations that are Callable by the Creditor* (SFAS 78), we have reclassified all of our long-term debt to current debt at December 31, 2008 and June 30, 2008.

Table of Contents

On September 22, 2006, NAIE, our wholly owned subsidiary, entered into a credit facility to provide it with a credit line of up to CHF 1,300,000, or approximately \$1.2 million, which is the initial maximum aggregate amount that can be outstanding at any one time under the credit facility. This maximum amount was reduced by CHF 160,000, or approximately \$152,000, as of December 31, 2007 and will be reduced by an additional CHF 160,000 at the end of each succeeding calendar year. On February 19, 2007, NAIE amended its credit facility to provide that the maximum aggregate amount that may be outstanding under the facility cannot be reduced below CHF 500,000, or approximately \$474,000. As of December 31, 2008, there was no outstanding balance under the credit facility.

Under its credit facility, NAIE may draw amounts either as current account loan credits to its current or future bank accounts or as fixed loans with a maximum term of 24 months. Current account loans will bear interest at the rate of 5% per annum. Fixed loans will bear interest at a rate determined by the parties based on current market conditions and must be repaid pursuant to a repayment schedule established by the parties at the time of the loan. If a fixed loan is repaid early at NAIE's election or in connection with the termination of the credit facility, NAIE will be charged a pre-payment penalty equal to 0.1% of the principal amount of the fixed loan or CHF 1,000 (approximately \$947), whichever is greater. The bank reserves the right to refuse individual requests for an advance under the credit facility, although its exercise of such right will not have the effect of terminating the credit facility as a whole.

The composite interest rate on all of our outstanding debt was 6.70% at December 31, 2008 and 8.23% at December 31, 2007.

F. Defined Benefit Pension Plan

We sponsor a defined benefit pension plan that provides retirement benefits to employees based generally on years of service and compensation during the last five years before retirement. Effective June 20, 1999, our Board of Directors amended the plan to freeze the accrued benefit of each plan member at its then current amount and to no longer allow inactive plan members or other employees to become active members of the plan. We contribute an amount not less than the minimum funding requirements of the Employee Retirement Income Security Act of 1974 nor more than the maximum tax-deductible amount.

The components included in the net periodic expense for the periods ended December 31 were as follows (in thousands):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2008	2007	2008	2007
Interest cost	\$ 20	\$ 21	\$ 40	\$ 42
Expected return on plan assets	(7)	(9)	(14)	(17)
Net periodic expense	\$ 13	\$ 12	\$ 26	\$ 25

G. Economic Dependency

We had substantial net sales to certain customers during the periods shown in the following table. The loss of any of these customers, or a significant decline in net sales or the growth rate of sales to these customers could have a material adverse impact on our net sales and net income. Net sales to any one customer representing 10% or more of the respective period's total net sales were as follows (dollars in thousands):

	Three Months Ended December 31,				Six Months Ended December 31,			
	2008		2007		2008		2007	
	Net Sales by Customer	% of Total Net Sales	Net Sales by Customer	% of Total Net Sales	Net Sales by Customer	% of Total Net Sales	Net Sales by Customer	% of Total Net Sales
Customer 1	\$ 9,034	51%	\$ 10,730	58%	\$ 18,907	51%	\$ 19,462	47%
Customer 2	4,132	23	4,640	25	9,533	26	13,814	34
Customer 3	1,959	11	(a)	(a)	(a)	(a)	(a)	(a)
	\$ 15,125	85%	\$ 15,370	83%	\$ 28,440	77%	\$ 33,276	81%

- (a) Net sales were less than 10% of the period's total net sales.

Table of Contents

We buy certain products from a limited number of raw material suppliers. The loss of any of these suppliers could have a material adverse impact on our net sales and net income. Raw material purchases from any one supplier representing 10% or more of the respective period's total raw material purchases were as follows (dollars in thousands):

	Three Months Ended December 31,				Six Months Ended December 31,			
	2008		2007		2008		2007	
	Raw Material Purchases by Supplier	% of Total Raw Material Purchases	Raw Material Purchases by Supplier	% of Total Raw Material Purchases	Raw Material Purchases by Supplier	% of Total Raw Material Purchases	Raw Material Purchases by Supplier	% of Total Raw Material Purchases
Supplier 1	\$ 1,233	14%	\$ (a)	(a)	\$ 2,048	11%	\$ 3,730	20%
Supplier 2	\$ 1,222	14%	586	11%	2,301	13	2,708	15
	\$ 2,455	28%	\$ 586	11%	\$ 4,349	24%	\$ 6,438	35%

(a) Purchases were less than 10% of the respective period's total raw material purchases.

H. Segment Information

Our business consists of two segments, as defined by SFAS No. 131, *Disclosures about Segments of an Enterprise and Related Information*, identified as private label contract manufacturing, which primarily provides private label contract manufacturing services to companies that market and distribute nutritional supplements and other health care products, and branded products, which markets and distributes branded nutritional supplements.

During the fourth quarter of fiscal 2008 we undertook a careful review of our branded products portfolio and operations. As a result of this review we decided to narrow our branded products focus and portfolio, which we expect to significantly improve our overall profitability and allow us to better pursue our growth strategies. As a result, before the end of fiscal 2008, we developed and approved a plan to sell the legacy RHL business. On August 4, 2008, RHL sold certain assets related to its catalog and internet business conducted under the name As We Change® to Miles Kimball Company for a cash purchase price of \$2,299,000.

We intend to market for sale legacy RHL's remaining business operations during fiscal 2009, with the exception of our Pathway to Healing® product line. As the plan to dispose of the legacy RHL business met the criteria of SFAS 144, the current and prior periods presented in this report have been reclassified to reflect the legacy RHL business as discontinued operations.

We evaluate performance based on a number of factors. The primary performance measures for each segment are net sales and income or loss from operations before corporate allocations. Operating income or loss for each segment does not include corporate general and administrative expenses, interest expense and other miscellaneous income and expense items. Corporate general and administrative expenses include, but are not limited to: human resources, legal, finance, information technology, and other corporate level related expenses, which are not allocated to either segment. The accounting policies of our segments are the same as those described in Note A above and in the consolidated financial statements included in our 2008 Annual Report.

Our operating results from continuing operations by business segment were as follows (in thousands):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2008	2007	2008	2007
Net Sales				
Private label contract manufacturing	\$ 16,978	\$ 17,387	\$ 35,720	\$ 39,205
Branded products	638	1,015	1,422	2,082

Edgar Filing: NATURAL ALTERNATIVES INTERNATIONAL INC - Form 10-Q

\$ 17,616 \$ 18,402 \$ 37,142 \$ 41,287

	Three Months Ended December 31,		Six Months Ended December 31,	
	2008	2007	2008	2007
(Loss) Income from Operations				
Private label contract manufacturing	\$ (70)	\$ 1,944	\$ 1,399	\$ 4,663
Branded products	70	130	118	276
Income from operations of reportable segments		2,074	1,517	4,939
Corporate expenses not allocated to segments	(2,066)	(1,973)	(3,801)	(3,790)
	\$ (2,066)	\$ 101	\$ (2,284)	\$ 1,149

Table of Contents

	December 31, 2008	June 30, 2008
Total Assets		
Private label contract manufacturing	\$ 38,407	\$ 39,479
Branded products	322	135
	\$ 38,729	\$ 39,614

Our private label contract manufacturing products are sold both in the United States and in markets outside the United States, including Europe, Australia and Japan. Our primary market outside the United States is Europe. Our branded products are sold only in the United States.

Net sales by geographic region, based on the customers' location, were as follows (in thousands):

	Three Months Ended December 31,		Six Months Ended December 31,	
	2008	2007	2008	2007
United States	\$ 11,669	\$ 13,294	\$ 24,863	\$ 29,899
Markets outside the United States	5,947	5,108	12,279	11,388
Total net sales	\$ 17,616	\$ 18,402	\$ 37,142	\$ 41,287

Products manufactured by NAIE accounted for approximately 52% of net sales in markets outside the United States for the three months ended December 31, 2008, and 62% for the three months ended December 31, 2007. NAIE accounted for 54% of net sales in markets outside the United States for the six months ended December 31, 2008, and 49% for the six months ended December 31, 2007. No products manufactured by NAIE were sold in the United States during the six months ended December 31, 2008 and 2007.

Assets and capital expenditures by geographic region, based on the location of the company or subsidiary at which they were located or made, were as follows (in thousands):

	Long-Lived Assets		Total Assets		Capital Expenditures Six Months Ended	
	December 31, 2008	June 30, 2008	December 31, 2008	June 30, 2008	December 31, 2008	December 31, 2007
United States	\$ 12,215	\$ 11,202	\$ 31,268	\$ 32,179	\$ 2,364	\$ 595
Europe	1,983	1,781	7,461	7,435	407	110
	\$ 14,198	\$ 12,983	\$ 38,729	\$ 39,614	\$ 2,771	\$ 705

I. Restructuring Costs

During the first six months of fiscal 2009, the continued decline in economic conditions in the United States and the various foreign markets we service negatively impacted our customers' businesses and our operations. As a result, during the second quarter of fiscal 2009 we implemented a cost reduction program that resulted in the elimination of certain personnel and business activities. The cost reduction program is expected to reduce the financial impact of the anticipated reduction in future sales. This program resulted in a charge to our operations of \$558,000 in severance from a reduction in force during the second quarter of fiscal 2009. All payments related to this cost reduction program are expected to be completed within the next twelve months.

The following table presents the activity and the reserve balance related to this restructuring program for the six months ended December 31, 2008 (in thousands):

Edgar Filing: NATURAL ALTERNATIVES INTERNATIONAL INC - Form 10-Q

	Balance at June 30, 2008	Charges to Expense	Cash Payments	Balance at December 31, 2008
Employee termination costs recorded to cost of goods sold	\$	\$ 187	\$ (65)	\$ 121
Employee termination costs recorded to selling, general and administrative expenses		371	(3)	368
Total	\$	\$ 558	\$ (68)	\$ 489

Table of Contents

J. Income Taxes

We account for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates, for each of the jurisdictions in which we operate, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.

At December 31, 2008, we recorded a valuation allowance against deferred income tax assets of \$1.9 million, representing the amount of our deferred income tax assets in excess of our deferred income tax liabilities. We recorded the valuation allowance because management was unable to conclude, in light of the cumulative loss we have realized related to our US-based operations for the three year period ended December 31, 2008, that realization of the net deferred income tax asset was more likely than not. The valuation allowance recorded during the quarter ended December 31, 2008 primarily related to the tax benefits of federal net operating loss carryforwards recognized in the first six months of fiscal 2009. As a result of the recognition of this valuation adjustment, we have a \$3.5 million gross deferred tax asset offset by a deferred tax liability of \$1.2 million and a valuation allowance of \$2.3 million resulting in a net deferred tax asset of zero as of December 31, 2008. This valuation allowance did not have any affect on the tax expense and related liability recorded for operating income recognized by our foreign subsidiary during the three and six months ended December 31, 2008.

On July 1, 2007 we adopted the provisions of the FASB Interpretation No. 48, *Accounting for Uncertainty in Income Taxes – An Interpretation of FASB Statement No. 109* (FIN 48). FIN 48 prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise's financial statements in accordance with FASB Statement No. 109, *Accounting for Income Taxes*. Tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized upon the adoption of FIN 48 and in subsequent periods. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Upon adoption of FIN 48 on July 1, 2007, we did not record any interest or penalties.

As of December 31, 2008 and June 30 2008, we had unrecognized tax liabilities of \$47,000. The total amount of unrecognized tax liabilities, if recognized, would not materially affect the effective tax rate.

We are subject to taxation in the United States, Switzerland and various state jurisdictions. Our tax years for the fiscal year ended June 30, 2006 and forward are subject to examination by the United States and state tax authorities and our tax years for the fiscal year ended June 30, 2007 and forward are subject to examination by the Switzerland tax authorities.

K. Contingencies

From time to time, we become involved in various investigations, claims and legal proceedings that arise in the ordinary course of our business. These matters may relate to product liability, employment, intellectual property, tax, regulation, contract or other matters. The resolution of these matters as they arise will be subject to various uncertainties and, even if such claims are without merit, could result in the expenditure of significant financial and managerial resources. While unfavorable outcomes are possible, based on available information, we generally do not believe the resolution of these matters will result in a material adverse effect on our business, consolidated financial condition, or results of operations. However, a settlement payment or unfavorable outcome could adversely impact our results of operations. Our evaluation of the likely impact of these actions could change in the future and we could have unfavorable outcomes that we do not expect.

As of February 17, 2009, neither NAI nor its subsidiaries were a party to any material pending legal proceeding nor was any of their property the subject of any material pending legal proceeding.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis is intended to help you understand our financial condition and results of operations for the three and six months ended December 31, 2008. You should read the following discussion and analysis together with our unaudited condensed consolidated financial statements and the notes to the condensed consolidated financial statements included under Item 1 in this report, as well as the risk factors and other information included in our 2008 Annual Report and other reports and documents we file with the SEC. Our future financial condition and results of operations will vary from our historical financial condition and results of operations described below based on a variety of factors.

Executive Overview

The following overview does not address all of the matters covered in the other sections of this Item 2 or other items in this report or contain all of the information that may be important to our stockholders or the investing public. This overview should be read in conjunction with the other sections of this Item 2 and this report.

Our primary business activity is providing private label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Historically, our revenue has been largely dependent on sales to one or two private label contract manufacturing customers and subject to variations in the timing of such customers' orders, which in turn is impacted by such customers' internal marketing programs, supply chain management, entry into new markets, new product introductions and general industry and economic conditions.

A cornerstone of our business strategy is to achieve long-term growth and profitability and to diversify our sales base. We have sought and expect to continue to seek to diversify our sales both by developing relationships with additional, quality-oriented, private label contract manufacturing customers and developing and growing our own line of branded products. In connection with our efforts to develop and grow our own line of branded products, we have determined to refine the types of products on which we will focus our efforts and in doing so have elected to discontinue certain of our branded products initiatives as described below.

During the fourth quarter of fiscal 2008, in an effort to enhance stockholder value, improve working capital and enable us to focus on our core contract manufacturing business, we elected to narrow our branded products focus and developed a plan to sell the legacy RHL business. On August 4, 2008, RHL sold certain assets related to its catalog and internet business conducted under the name As We Change® to Miles Kimball Company for a cash purchase price of \$2,000,000. The purchase price was subject to certain post-closing adjustments based on a final accounting of the value of the assets sold to and the liabilities assumed by the buyer at the closing. As a result of the post-closing review, the purchase price was increased by \$299,000, resulting in an aggregate purchase price of \$2,299,000. We recorded a loss, net of tax, of \$148,000 as a result of this sale and recognized \$221,000 in severance and related payroll costs during the six months ended December 31, 2008. We intend to market for sale legacy RHL's remaining business operations during fiscal 2009, with the exception of our Pathway to Healing® product line. The financial information presented in this report has been reclassified to reflect the legacy RHL business as discontinued operations.

As a result of our decision to sell the legacy RHL business, we also initiated an operational consolidation program during the first quarter of fiscal 2009 that transitioned the remaining branded products business operations to our corporate offices. This operational consolidation program was substantially complete as of September 30, 2008 and resulted in a charge to discontinued operations of \$829,000 in severance and other business related exit costs during the six months ended December 31, 2008.

During the first six months of fiscal 2009, our net sales from continuing operations were 10.0% lower than in the first six months of fiscal 2008. Private label contract manufacturing sales declined 8.9% primarily due to lower volumes of existing products in existing markets sold to one of our largest customers, unfavorable foreign currency fluctuations, and economic conditions. Net sales from our branded products declined 31.7% in the first six months of fiscal 2009 as compared to the first six months of fiscal 2008 due to the continued softening of our Pathway to Healing® product line.

Our revenue concentration risk for our two largest customers decreased to 77% as a percentage of our total sales from continuing operations for the first six months of fiscal 2009 compared to 81% in the first six months of fiscal 2008. We expect our contract manufacturing revenue concentration percentage for our two largest customers to remain consistent for the remainder of fiscal 2009.

During fiscal 2008, we invested substantial time and incurred substantial costs associated with hiring and training new quality assurance and other manufacturing support personnel, increased testing activity, and documentation and validation processes related to our Good Manufacturing Practices (GMPs) compliance programs and we expect to continue to make investments related to our GMPs through fiscal 2009. These additional expenses negatively impacted our gross margin from continuing operations during fiscal 2008 and the first six months of fiscal 2009 and we expect this trend to continue during fiscal 2009 until we increase the volume of our private label business sufficiently to offset our

higher fixed overhead structure. Although the cost of GMP compliance is

Table of Contents

significant, we believe our commitment to quality and our steadfast support of the FDA mandated GMPs makes us well positioned to operate within the higher standards of the Food and Drug Administration's GMPs and differentiates us from our competitors.

During our first six months of fiscal 2009, the continued decline in economic conditions in the United States and the various foreign markets we service negatively impacted our customers' businesses and our operations. As a result, during the second quarter of fiscal 2009 we implemented a cost reduction program that resulted in the elimination of certain personnel and business activities. The cost reduction program is expected to reduce the financial impact of the anticipated reduction in future sales. This program resulted in a charge to our operations of \$558,000 during the second quarter of fiscal 2009 and is expected to reduce our operating overhead costs by approximately \$3.6 million annually.

Beginning in April 2007, Dr. Cherry ceased airing his weekly television program, which had served as the primary customer acquisition vehicle in marketing the Pathway to Healing® product line. While sales of the product line have been primarily generated by continuity orders from long-standing repeat customers, the loss of the television program has had a negative impact on our ability to acquire new customers. We continue working with Dr. Cherry to evaluate alternative marketing programs and revise marketing plans to support the product line.

During fiscal 2009, we plan to continue to focus on:

Leveraging our state of the art, certified facilities to increase the value of the goods and services we provide to our highly valued private label contract manufacturing customers, and assist us in developing relationships with additional quality oriented customers;

Implementing focused initiatives to grow our Pathway to Healing® product line;

Improving operational efficiencies and managing costs and business risks to improve profitability.

During fiscal 2009, in connection with our efforts to leverage our state of the art facilities, we received recertification of our Swissmedic Authority pharmaceutical license for our Manno, Switzerland manufacturing facility and our Therapeutic Goods Administration (TGA) of Australia certification for our Vista, California manufacturing facilities.

Looking forward, as a result of the uncertain near-term economic conditions including unfavorable currency markets, we expect reduced net sales from both our branded products and contract manufacturing businesses along with higher per unit operating costs related to our reduced manufacturing throughput in the third quarter of fiscal 2009, as compared to the third quarter in fiscal 2008. The negative effect on our operations associated with the anticipated decline in our third quarter sales is expected to be offset by the cost reduction program we implemented during the second quarter of fiscal 2009.

Critical Accounting Policies and Estimates

The preparation of our financial statements requires that we make estimates and assumptions that affect the amounts reported in our financial statements and their accompanying notes. We have identified certain policies that we believe are important to the portrayal of our financial condition and results of operations. These policies require the application of significant judgment by our management. We base our estimates on our historical experience, industry standards, and various other assumptions that we believe are reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. An adverse effect on our financial condition, changes in financial condition, and results of operations could occur if circumstances change that alter the various assumptions or conditions used in such estimates or assumptions.

Our critical accounting policies are discussed under Item 7 of our 2008 Annual Report. There have been no significant changes to these policies during the six months ended December 31, 2008.

Table of Contents**Results of Operations**

The results of our operations for the periods ended December 31 were as follows (in thousands):

	Three Months Ended December 31,			Six Months Ended December 31,		
	2008	2007	% Change	2008	2007	% Change
Private label contract manufacturing	\$ 16,978	\$ 17,387	(2)	\$ 35,720	\$ 39,205	(9)
Branded products	638	1,015	(37)	1,422	2,082	(32)
Total net sales	17,616	18,402	(4)	37,142	41,287	(10)
Cost of goods sold	16,844	15,226	(11)	33,970	34,171	(1)
Gross profit	772	3,176	(76)	3,172	7,116	(55)
Gross profit %	4.4%	17.3%		8.5%	17.2%	
Selling, general & administrative expenses	2,838	3,075	(8)	5,456	5,967	(9)
% of net sales	16.1%	16.7%		14.7%	14.5%	
Operating (loss) income from continuing operations	(2,066)	101	(2,146)	(2,284)	1,149	(299)
% of net sales	(11.7%)	0.5%		(6.1%)	2.8%	
Other expense, net	120	8	1,400	433	19	2,179
(Loss) income from continuing operations before income taxes	(2,186)	93	(2,451)	(2,717)	1,130	